| The modification role and tumor association with a methyltransferase: KMT2C. | The modification role and tumor association with a methyltransferase: KMT2C.
Jiao Y, Lv Y, Liu M, Liu Y, Han M, Xiong X, Zhou H, Zhong J, Kang X, Su W., Free PMC Article | 08/23/2024 |
| Pathogenic variants in KMT2C result in a neurodevelopmental disorder distinct from Kleefstra and Kabuki syndromes. | Pathogenic variants in KMT2C result in a neurodevelopmental disorder distinct from Kleefstra and Kabuki syndromes.
Rots D, Choufani S, Faundes V, Dingemans AJM, Joss S, Foulds N, Jones EA, Stewart S, Vasudevan P, Dabir T, Park SM, Jewell R, Brown N, Pais L, Jacquemont S, Jizi K, Ravenswaaij-Arts CMAV, Kroes HY, Stumpel CTRM, Ockeloen CW, Diets IJ, Nizon M, Vincent M, Cogné B, Besnard T, Kambouris M, Anderson E, Zackai EH, McDougall C, Donoghue S, O'Donnell-Luria A, Valivullah Z, O'Leary M, Srivastava S, Byers H, Leslie N, Mazzola S, Tiller GE, Vera M, Shen JJ, Boles R, Jain V, Brischoux-Boucher E, Kinning E, Simpson BN, Giltay JC, Harris J, Keren B, Guimier A, Marijon P, Vries BBA, Motter CS, Mendelsohn BA, Coffino S, Gerkes EH, Afenjar A, Visconti P, Bacchelli E, Maestrini E, Delahaye-Duriez A, Gooch C, Hendriks Y, Adams H, Thauvin-Robinet C, Josephi-Taylor S, Bertoli M, Parker MJ, Rutten JW, Caluseriu O, Vernon HJ, Kaziyev J, Zhu J, Kremen J, Frazier Z, Osika H, Breault D, Nair S, Lewis SME, Ceroni F, Viggiano M, Posar A, Brittain H, Giovanna T, Giulia G, Quteineh L, Ha-Vinh Leuchter R, Zonneveld-Huijssoon E, Mellado C, Marey I, Coudert A, Aracena Alvarez MI, Kennis MGP, Bouman A, Roifman M, Amorós Rodríguez MI, Ortigoza-Escobar JD, Vernimmen V, Sinnema M, Pfundt R, Brunner HG, Vissers LELM, Kleefstra T, Weksberg R, Banka S., | 08/13/2024 |
| A novel 11 base pair deletion in KMT2C resulting in Kleefstra syndrome 2. | A novel 11 base pair deletion in KMT2C resulting in Kleefstra syndrome 2.
Whitford W, Taylor J, Hayes I, Smith W, Snell RG, Lehnert K, Jacobsen JC., Free PMC Article | 02/4/2024 |
| Association of KMT2C/D loss-of-function variants with response to immune checkpoint blockades in colorectal cancer. | Association of KMT2C/D loss-of-function variants with response to immune checkpoint blockades in colorectal cancer.
Liu R, Niu Y, Liu C, Zhang X, Zhang J, Shi M, Zou W, Gu B, Zhu H, Wang D, Yuan H, Li W, Zhao D, Zheng Q, Liu R, Chen W, Ma T, Zhang Y., Free PMC Article | 08/11/2023 |
| Mutations in epigenetic regulator KMT2C detected by liquid biopsy are associated with worse survival in prostate cancer patients. | Mutations in epigenetic regulator KMT2C detected by liquid biopsy are associated with worse survival in prostate cancer patients.
Zhu S, Xu N, Liang J, Zhao F, Wang Z, Ni Y, Dai J, Zhao J, Zhang X, Chen J, Sun G, Shen P, Zeng H., Free PMC Article | 07/12/2023 |
| MLL3 regulates the CDKN2A tumor suppressor locus in liver cancer. | MLL3 regulates the CDKN2A tumor suppressor locus in liver cancer.
Zhu C, Soto-Feliciano YM, Morris JP, Huang CH, Koche RP, Ho YJ, Banito A, Chen CW, Shroff A, Tian S, Livshits G, Chen CC, Fennell M, Armstrong SA, Allis CD, Tschaharganeh DF, Lowe SW., Free PMC Article | 06/26/2023 |
| Association of MLL3 and TGF-beta signaling gene polymorphisms with the susceptibility and prognostic outcomes of Stanford type B aortic dissection : MLL3 with TGF-beta signal pathway association with Stanford type B AD. | Association of MLL3 and TGF-β signaling gene polymorphisms with the susceptibility and prognostic outcomes of Stanford type B aortic dissection : MLL3 with TGF-β signal pathway association with Stanford type B AD.
Yuan Q, Chang Y, Jiang P, Sun L, Ma Y, Ma X., Free PMC Article | 06/1/2023 |
| MLL3 loss drives metastasis by promoting a hybrid epithelial-mesenchymal transition state. | MLL3 loss drives metastasis by promoting a hybrid epithelial-mesenchymal transition state.
Cui J, Zhang C, Lee JE, Bartholdy BA, Yang D, Liu Y, Erler P, Galbo PM Jr, Hodge DQ, Huangfu D, Zheng D, Ge K, Guo W., Free PMC Article | 02/4/2023 |
| KMT2C Induced by FABP5P3 Aggravates Keratinocyte Hyperproliferation and Psoriasiform Skin Inflammation by Upregulating the Transcription of PIK3R3. | KMT2C Induced by FABP5P3 Aggravates Keratinocyte Hyperproliferation and Psoriasiform Skin Inflammation by Upregulating the Transcription of PIK3R3.
Huang S, Zhen Y, Yin X, Yang Z, Li X, Wang R, Wen H, Zhong H, Yan J, Sun Q. | 12/24/2022 |
| Histone methyltransferase KMT2C plays an oncogenic role in prostate cancer. | Histone methyltransferase KMT2C plays an oncogenic role in prostate cancer.
Lian J, Xu C, Chen X, Huang S, Wu D. | 06/18/2022 |
| KMT2C is a Potential Biomarker of Anti-PD-1 Treatment Response in Metastatic Melanoma. | KMT2C is a Potential Biomarker of Anti-PD-1 Treatment Response in Metastatic Melanoma.
Xie K, Peng Y, Zhong W, Liu X. | 05/7/2022 |
| Association of KMT2C Genetic Variants with the Clinicopathologic Development of Oral Cancer. | Association of KMT2C Genetic Variants with the Clinicopathologic Development of Oral Cancer.
Shieu MK, Ho HY, Lin SH, Lo YS, Lin CC, Chuang YC, Hsieh MJ, Chen MK., Free PMC Article | 04/23/2022 |
| KMT2C methyltransferase domain regulated INK4A expression suppresses prostate cancer metastasis. | KMT2C methyltransferase domain regulated INK4A expression suppresses prostate cancer metastasis.
Limberger T, Schlederer M, Trachtová K, Garces de Los Fayos Alonso I, Yang J, Högler S, Sternberg C, Bystry V, Oppelt J, Tichý B, Schmeidl M, Kodajova P, Jäger A, Neubauer HA, Oberhuber M, Schmalzbauer BS, Pospisilova S, Dolznig H, Wadsak W, Culig Z, Turner SD, Egger G, Lagger S, Kenner L., Free PMC Article | 04/9/2022 |
| KMT2C promoter methylation in plasma-circulating tumor DNA is a prognostic biomarker in non-small cell lung cancer. | KMT2C promoter methylation in plasma-circulating tumor DNA is a prognostic biomarker in non-small cell lung cancer.
Mastoraki S, Balgkouranidou I, Tsaroucha E, Klinakis A, Georgoulias V, Lianidou E., Free PMC Article | 04/2/2022 |
| H3K4 Methylation Status and Lysine Specific Methyltransferase KMT2C Expression Correlate with Prognosis in Lung Adenocarcinoma. | H3K4 Methylation Status and Lysine Specific Methyltransferase KMT2C Expression Correlate with Prognosis in Lung Adenocarcinoma.
Bosgana P, Nikou S, Dimitrakopoulos FI, Logotheti S, Tzelepi V, Kalophonos C, Bravou V, Kourea E, Sampsonas F, Zolota V. | 04/2/2022 |
| Two new cases of interstitial 7q35q36.1 deletion including CNTNAP2 and KMT2C. | Two new cases of interstitial 7q35q36.1 deletion including CNTNAP2 and KMT2C.
Tosca L, Drévillon L, Mouka A, Lecerf L, Briand A, Ortonne V, Benoit V, Brisset S, Van Maldergem L, Laudouar Q, Heide S, Goossens M, Giurgea I, Tachdjian G, Métay C., Free PMC Article | 03/19/2022 |
| MLL3 is a de novo cause of endocrine therapy resistance. | MLL3 is a de novo cause of endocrine therapy resistance.
Stauffer KM, Elion DL, Cook RS, Stricker T., Free PMC Article | 03/19/2022 |
| The MLL3/4 H3K4 methyltransferase complex in establishing an active enhancer landscape. | The MLL3/4 H3K4 methyltransferase complex in establishing an active enhancer landscape.
Wang LH, Aberin MAE, Wu S, Wang SP., Free PMC Article | 02/5/2022 |
| MLL3 Inhibits Apoptosis of Rheumatoid Arthritis Fibroblast-Like Synoviocytes and Promotes Secretion of Inflammatory Factors by Activating CCL2 and the NF-kappaB Pathway. | MLL3 Inhibits Apoptosis of Rheumatoid Arthritis Fibroblast-Like Synoviocytes and Promotes Secretion of Inflammatory Factors by Activating CCL2 and the NF-κB Pathway.
Fan W, Xu Z, Liang S, Zuo S, Bian C, Gao X, Qin Y, Wu J. | 02/5/2022 |
| Recruitment of KMT2C/MLL3 to DNA Damage Sites Mediates DNA Damage Responses and Regulates PARP Inhibitor Sensitivity in Cancer. | Recruitment of KMT2C/MLL3 to DNA Damage Sites Mediates DNA Damage Responses and Regulates PARP Inhibitor Sensitivity in Cancer.
Chang A, Liu L, Ashby JM, Wu D, Chen Y, O'Neill SS, Huang S, Wang J, Wang G, Cheng D, Tan X, Petty WJ, Pasche BC, Xiang R, Zhang W, Sun P., Free PMC Article | 12/18/2021 |
| Cancer gene mutation frequencies for the U.S. population. | Cancer gene mutation frequencies for the U.S. population.
Mendiratta G, Ke E, Aziz M, Liarakos D, Tong M, Stites EC., Free PMC Article | 11/6/2021 |
| MLL3 suppresses tumorigenesis through regulating TNS3 enhancer activity. | MLL3 suppresses tumorigenesis through regulating TNS3 enhancer activity.
Zheng JY, Wang CY, Gao C, Xiao Q, Huang CW, Wu M, Li LY., Free PMC Article | 09/25/2021 |
| KMT2C/D COMPASS complex-associated diseases [KCDCOM-ADs]: an emerging class of congenital regulopathies. | KMT2C/D COMPASS complex-associated diseases [K(CD)COM-ADs]: an emerging class of congenital regulopathies.
Lavery WJ, Barski A, Wiley S, Schorry EK, Lindsley AW., Free PMC Article | 08/21/2021 |
| Restoration of KMT2C/MLL3 in human colorectal cancer cells reinforces genome-wide H3K4me1 profiles and influences cell growth and gene expression. | Restoration of KMT2C/MLL3 in human colorectal cancer cells reinforces genome-wide H3K4me1 profiles and influences cell growth and gene expression.
Larsson C, Cordeddu L, Siggens L, Pandzic T, Kundu S, He L, Ali MA, Pristovšek N, Hartman K, Ekwall K, Sjöblom T., Free PMC Article | 08/21/2021 |
| Acquired Cystic Kidney Disease-associated Renal Cell Carcinoma (ACKD-RCC) Harbor Recurrent Mutations in KMT2C and TSC2 Genes. | Acquired Cystic Kidney Disease-associated Renal Cell Carcinoma (ACKD-RCC) Harbor Recurrent Mutations in KMT2C and TSC2 Genes.
Shah A, Lal P, Toorens E, Palmer MB, Schwartz L, Vergara N, Guzzo T, Nayak A. | 12/19/2020 |